Archive · 7 Nov 2025
India's Pharma Sector: Two Small-Cap Growth Potential Stocks
Imagine you're looking for hidden treasures in a big garden.
India's medicine-making industry is like a big garden that's growing fast and making lots of money.
While everyone is looking at the giant, sparkly flowers, there are two smaller, less noticed plants, called Jenburkt and Jagsonpal, that are also growing very strong roots and promising to bloom well.
They are making more money from the money they use than many other companies, are paying back their debts, and are even giving some of their profits back to the people who own them, like giving you a small treat.
They’ve also gotten much better at getting their money back quickly after spending it.
While they are small and a bit riskier like a young sapling, their past performance shows they might become big players in the future.
It’s like finding a secret gem before everyone else does.
India is a global leader in generic drugs and vaccines, with its pharmaceutical sector projected to double in value by 2030.
Jenburkt Pharmaceuticals Ltd. shows strong capital efficiency with a 27% ROCE, near-zero debt, and a reduced cash conversion cycle.
Jagsonpal Pharmaceuticals Ltd. also exhibits strong performance with a 23% ROCE, minimal debt, and a significantly improved cash conversion cycle.
Both Jenburkt and Jagsonpal have provided substantial returns to investors over the last five years and offer attractive dividend yields compared to the industry.
While promising, both companies are small-caps, which inherently carry higher risk due to limited information and market coverage.
- Who
- Jenburkt Pharmaceuticals Ltd. and Jagsonpal Pharmaceuticals Ltd.
- What
- Two Indian pharmaceutical small-cap companies showing signs of sustainable growth and strong financial performance.
- When
- The article analyzes data from FY20 to FY25 and discusses current market conditions up to November 2025.
- Where
- India
- Why
- The Indian pharmaceutical industry is experiencing significant growth, driven by government initiatives and increasing global demand, presenting opportunities for under-the-radar companies.
- Jenburkt Pharma Market Cap
- Rs 536 cr
- Jagsonpal Pharma Market Cap
- Rs 1,448 cr
- Jenburkt Pharma ROCE
- 27%
- Jagsonpal Pharma ROCE
- 23%
- Industry Median ROCE
- 15%
- Jenburkt Pharma Dividend Yield
- 1.48%
- Jagsonpal Pharma Dividend Yield
- 1.14%
- Industry Median Dividend Yield
- 0.12%